Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis

Leukemia Research and Treatment
Ursula RochauUwe Siebert

Abstract

Currently several tyrosine kinase inhibitors (TKIs) are approved for treatment of chronic myeloid leukemia (CML). Our goal was to identify the optimal sequential treatment strategy in terms of effectiveness and cost-effectiveness for CML patients within the US health care context. We evaluated 18 treatment strategies regarding survival, quality-adjusted survival, and costs. For model parameters, the literature data, expert surveys, registry data, and economic databases were used. Evaluated strategies included imatinib, dasatinib, nilotinib, bosutinib, ponatinib, stem-cell transplantation (SCT), and chemotherapy. We developed a Markov state-transition model, which was analyzed as a cohort simulation over a lifelong time horizon with a third-party payer perspective and discount rate of 3%. Remaining life expectancies ranged from 5.4 years (3.9 quality-adjusted life years (QALYs)) for chemotherapy treatment without TKI to 14.4 years (11.1 QALYs) for nilotinib→dasatinib→chemotherapy/SCT. In the economic evaluation, imatinib→chemotherapy/SCT resulted in an incremental cost-utility ratio (ICUR) of $171,700/QALY compared to chemotherapy without TKI. Imatinib→nilotinib→chemotherapy/SCT yielded an ICUR of $253,500/QALY compared to imati...Continue Reading

References

Apr 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·D G FrybackP A Martin
Mar 16, 2000·Health Affairs·P J NeumannR H Chapman
Jul 30, 2003·Archives of Internal Medicine·Peter A UbelA Mark Fendrick
Jan 25, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Akiko M SaitoStephanie J Lee
Jun 11, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil P ShahAndreas Hochhaus
Jun 8, 2010·The New England Journal of Medicine·Giuseppe SaglioUNKNOWN ENESTnd Investigators
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Nov 3, 2010·British Medical Bulletin·Sarah J Whitehead, Shehzad Ali
Mar 15, 2011·The American Journal of Medicine·David U HimmelsteinSteffie Woolhandler
Dec 14, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Martin HoyleKen Stein
Sep 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesCarlo Gambacorti-Passerini
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·J Jaime CaroUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Mark RobertsUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Uwe SiebertKaren M Kuntz
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Andrew H BriggsUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·David M EddyUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BaccaraniUNKNOWN ESMO Guidelines Working Group
Oct 29, 2013·Leukemia & Lymphoma·Ursula RochauUwe Siebert
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Aug 8, 2014·Journal of the National Comprehensive Cancer Network : JNCCN·David D StenehjemDiana I Brixner

❮ Previous
Next ❯

Software Mentioned

HCUPnet
TreeAge

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.